Acute progranulocytic leukemia

Current Opinion in Oncology

Volumn 13, Issue 1, 2001, Pages 8-13

  Powell, Bayard L ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ARABINOSIDE; ARSENIC TRIOXIDE; CYTOSINE; MONOCLONAL ANTIBODY; RETINOIC ACID;

ACUTE KIDNEY FAILURE; APOPTOSIS; BLOOD CLOTTING DISORDER; CLINICAL FEATURE; DRUG EFFICACY; FEVER; HUMAN; HYPOTENSION; LEUKEMIA REMISSION; LUNG INFILTRATE; PATHOPHYSIOLOGY; PATIENT CARE; PERICARDIAL EFFUSION; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROMYELOCYTIC LEUKEMIA; RELAPSE; RESPIRATORY DISTRESS; REVIEW; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; SURVIVAL RATE; WEIGHT GAIN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ARSENICALS; CLINICAL TRIALS; CYTARABINE; HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; NEOPLASM, RESIDUAL; OXIDES; PROGNOSIS; SALVAGE THERAPY; SURVIVAL ANALYSIS; TRETINOIN; TUMOR MARKERS, BIOLOGICAL;

EID: 0035173424     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200101000-00003     Document Type: Review

References (45)

1. Proposed revised criteria for the classification of acute myeloid leukemia
2. The unique aspects of acute promyelocytic leukemia
3. Acute promyelocytic leukaemia: A study of 39 cases with identification of a hyperbasophilic microgranular variant
4. Morphology of acute promyelocytic leukemia with cytogenetic or molecular evidence for the diagnosis: Characterization of additional microgranular variants
5. Morphological classification, response to therapy, and survival in 263 adult patients with acute nonlymphoblastic leukemia
6. Analysis of risk factors for fatal hemorrhage during induction therapy of patients with acute promyelocytic leukemia
7. New insights into the pathogenesis of coagulation dysfunction in actue promyelocytic leukemia
8. Acute promyelocytic leukemia: Therapy results and prognostic factors
9. Evidence for a 15;17 translocation in every patient with acute promyelocytic leukemia
10. Acute promyelocytic leukemia: From morphology to molecular lesions
11. Combined cytogenetic, FISH and molecular analysis in acute promyelocytic leukaemia at diagnosis and in complete remission
12. Improved rapid detection of the PML/RARalpha fusion gene in acute promyelocytic leukemia
13. Terminal differentiation of human promyelocytic leukemic cells in primary culture in response to retinoic acid
14. Mapping of the human retinoic acid receptor to the q21 band of chromosome 17
15. Deconstructing a disease: RARα1 its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia
16. PML is essential for multiple apoptotic pathways
17. Current issues in the management of acute promyelocytic leukemia
18. All-trans-retinoic acid in acute promyelocytic leukemia
19. Effect of all trans-retinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial
20. Tretinoin with chemotherapy in newly diagnosed acute promyelocytic leukaemia
21. A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia
22. Molecular remission in PML/RARα positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA)therapy
23. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα-positive acute promyelocytic leukemia
24. Arsenic trioxide treated 72 cases of acute promyelocytic leukemia
25. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL):I. As203 exerts dose-dependent dual effects on APL cells
26. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia: Il. Clinical efficacy and pharmacokinetics in relapsed patients
27. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide
28. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SClD mice
29. Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia
30. 3) in the treatment of acute promyelocytic leukemia
31. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
32. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia
33. Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HUM195 in acute promyelocytic leukemia
34. Treatment of relapsing acute promyelocytic leukemia by all-trans retinoic acid therapy followed by timed sequential chemotherapy and stem cell transplantation
35. Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia
36. Quantitation of minimal residual disease in acute promyelocytic leukemia patients with t(15;17) translocation using real-time RT-PCR
37. Early detection of relapse by prospective reverse transcriptase- polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial
38. Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: Result of the randomized MRC trial
39. Therapy of molecular relapse in acute promyelocytic leukemia
40. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy
41. CD56 expression in acute promyelocytic leukemia: A possible indicator of poor treatment outcome?
42. HLA class I in acute promyelocytic leukemia (APL): Possible correlation with clinical outcome
43. The thrombophilic state in acute promyelocytic leukemia
44. Clinical description of 44 patients with acute promyelocytic leukemia who developed the retinoic acid syndrome
45. Extramedullary relapse after all-trans retinoic acid treatment in acute promyelocytic leukemia-the occurrence of retinoic acid syndrome is a risk factor